Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, has announced it will release its fourth quarter and fiscal year 2024 financial results on March 26, 2025. The company, which develops in vivo gene editing therapies using its proprietary ARCUS® platform, will also provide a business update. Their platform technology focuses on gene elimination, gene insertion, and gene excision programs.
Precision BioSciences (Nasdaq: DTIL), un'azienda di editing genetico in fase clinica, ha annunciato che pubblicherà i suoi risultati finanziari del quarto trimestre e dell'anno fiscale 2024 il 26 marzo 2025. L'azienda, che sviluppa terapie di editing genetico in vivo utilizzando la sua piattaforma proprietaria ARCUS®, fornirà anche un aggiornamento aziendale. La loro tecnologia di piattaforma si concentra su programmi di eliminazione, inserimento ed escissione genica.
Precision BioSciences (Nasdaq: DTIL), una empresa de edición genética en etapa clínica, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año fiscal 2024 el 26 de marzo de 2025. La empresa, que desarrolla terapias de edición genética in vivo utilizando su plataforma propietaria ARCUS®, también proporcionará una actualización empresarial. Su tecnología de plataforma se centra en programas de eliminación, inserción y excisión de genes.
Precision BioSciences (Nasdaq: DTIL), 임상 단계의 유전자 편집 회사는 2024 회계연도 및 4분기 재무 결과를 2025년 3월 26일에 발표할 것이라고 발표했습니다. 이 회사는 독자적인 ARCUS® 플랫폼을 사용하여 인 비보 유전자 편집 치료제를 개발하며, 비즈니스 업데이트도 제공할 예정입니다. 그들의 플랫폼 기술은 유전자 제거, 유전자 삽입 및 유전자 절제 프로그램에 중점을 두고 있습니다.
Precision BioSciences (Nasdaq: DTIL), une entreprise de modification génétique en phase clinique, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'exercice 2024 le 26 mars 2025. L'entreprise, qui développe des thérapies d'édition génétique in vivo en utilisant sa plateforme propriétaire ARCUS®, fournira également une mise à jour commerciale. Leur technologie de plateforme se concentre sur des programmes d'élimination, d'insertion et d'excision de gènes.
Precision BioSciences (Nasdaq: DTIL), ein Unternehmen für Gen-Editing in der klinischen Phase, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2024 am 26. März 2025 veröffentlichen wird. Das Unternehmen, das in vivo-Gentherapien mit seiner proprietären ARCUS®-Plattform entwickelt, wird auch ein Unternehmensupdate bereitstellen. Ihre Plattformtechnologie konzentriert sich auf Programme zur Geneliminierung, Geninsertierung und Genexzision.
- None.
- None.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250321857482/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Source: Precision BioSciences, Inc.
FAQ
When will Precision BioSciences (DTIL) release its Q4 and FY 2024 earnings?
What is the main technology platform used by Precision BioSciences (DTIL)?
What types of gene editing programs does DTIL develop?
What is the current development stage of Precision BioSciences (DTIL)?
